Graft-versus-host disease (GVHD) is a major complication of allogenic bone marrow transplantation and involves the infiltration of donor CD4 + and/or CD8 + T cells into various organs of the recipient. The pathological role of human CD4 + and CD8 + T cells in GVHD remains controversial. In this study, we established two novel xenogeneic (xeno)-GVHD models. Human CD4 + or CD8 + T cells were purified from peripheral blood and were transplanted into immunodeficient NOD/Shi-scid IL2rg null (NOG) mice. Human CD8 + T cells did not induce major GVHD symptoms in conventional NOG mice. However, CD8 + T cells immediately proliferated and induced severe GVHD when transferred into NOG mice together with at least 0.5 3 10 6 CD4 + T cells or into NOG human interleukin (IL)-2 transgenic mice. Human CD4 + T cell-transplanted NOG mice developed skin inflammations including alopecia, epidermal hyperplasia, and neutrophilia. Pathogenic T helper (Th)17 cells accumulated in the skin of CD4 + T cell-transplanted NOG mice. Further, an anti-human IL-17 antibody (secukinumab) significantly suppressed these skin pathologies. These results indicate that pathogenic human Th17 cells induce cutaneous GVHD via IL-17-dependent pathways. This study provides fundamental insights into the pathogenesis of xeno-GVHD, and these humanized mouse models may be useful as preclinical tools for the prevention of GVHD.
Introduction
Graft-versus-host disease (GVHD) is a severe adverse effect that results from allogenic (allo) bone marrow transplantation and has a high rate of mortality (1) . Allo-GVHD is initiated when donor CD4 + or CD8 + T cells are activated and infiltrate various recipient tissues including the skin, gut, liver, and lungs. They recognize major histocompatibility complex (MHC) class I or class II molecules in the recipient (2, 3) .
Different types of peripheral CD4
+ T cells (T helper [Th]1, Th2, and Th17) are generated by distinct cytokines. Na€ ıve CD4 + T cells differentiate into interferon gamma (IFNc)-producing Th1 cells or interleukin 4 (IL-4)-producing Th2 cells as a result of IL-12 or IL-4 stimulation. Transforming growth factor-b, IL-6, IL-1b, and IL-23 induce the development of IL-17-producing Th17 cells (4) . In addition, pathogenic Th17 cells produce both IFNc and IL-17 and differentiate from Th17 cells during allo-stimulation (5).
These cells contribute to inflammatory diseases such as chronic GVHD, experimental autoimmune encephalomyelitis, and colitis (6) (7) (8) . CD8 + T cells also contribute to GVHD pathogenesis by infiltrating target tissues, where they are activated by allo-stimulation. After CD8 + T cell activation, apoptosis is induced in the recipient through perforin-or FAS-FASL-dependent pathways (9, 10) . Although murine models have been generated to investigate the pathogenic roles of CD4 + or CD8 + T cells in GVHD, in vivo models using human cells are limited.
A xenograft animal model using immunodeficient mouse is widely used to investigate various human diseases including GVHD. NOD-scid IL2rg null (NOG or NSG) mice are the superior immunodeficient mice for receiving a xenotransplant. They lack T, B, and natural killer cells, and their innate immune cells do not function properly, including dendritic cells and macrophages (11) (12) (13) . In these mice, various human cells or tissues can be efficiently engrafted because of this severe immunodeficiency. These humanized mice are able to mimic various human diseases, including cancer and infectious, allergic, and autoimmune disorders (14) (15) (16) (17) (18) (19) .
We previously developed a highly sensitive xenogeneic (xeno)-GVHD model by transferring human peripheral blood mononuclear cells (PBMCs) into NOG mice (20) . In these mice, GVHD was immediately induced by engrafted human T cells compared with other immunodeficient strains, and both human CD4 + and CD8 + T cells were able to infiltrate the recipient organs. Covassin et al developed a human allo-GVHD model by transplanting human CD4 + T cells into NSG-HLA-DR4 transgenic (Tg) mice (21) . They induced a human allo-GVH reaction in this strain, and transplanted human CD4 + T cells recognized allo-HLA class II molecules.
These models are useful for studying the pathogenesis of human GVHD. However, the role of individual human T cell subsets in GVHD has not been fully elucidated. Here, we examined the roles of human CD4 + and CD8 + T cells during xeno-GVHD in NOG mice. We developed novel models for studying (a) CD8 + T cell-mediated GVHD by using human IL-2 Tg mice and (b) pathogenic Th17 cell-mediated cutaneous GVHD by human CD4 + T cell transplantation. Using these models, the mechanisms of GVHD pathogenesis can be investigated and may have useful applications in preclinical studies.
Materials and Methods

Ethics statement
All animal experiments were approved by the Institutional Animal Care and Use Committee of the Central Institute for Experimental Animals (CIEA) (Certification Number: 14038) and were performed in accordance with CIEA guidelines. All experiments using human cells were approved by the Institutional Ethical Committee of the CIEA (Certification Number: 08-11) and performed in accordance with CIEA guidelines. Written informed consent was obtained from all subjects. Tg (CMV-IL2)4-2Jic/Jic] mice (24) were established in CIEA and were bled under specific pathogen-free conditions. Mice had access to sterilized food and water ad libitum and were used for human cell transplantation studies at 8-10 weeks of age.
Mice
Transplantation of human CD4 + and CD8 + T cells
Human peripheral blood (PB) was collected from healthy volunteers after informed consent was obtained. Human PBMCs were separated by the use of Lymphoprep (Axis-Shields, Oslo, Norway) density centrifugation and washed with phosphate-buffered saline (PBS). Human CD4 + or CD8 + T cells were isolated with anti-human CD4 or CD8 magnetic beads by using a MACS column (Miltenyi Biotec, Sunnyvale, CA) according to the manufacturer's instructions. Purified human CD4 + or CD8 + T cells were resuspended in PBS and intravenously injected (2 9 10 6 cells) into the tail vein of NOG mice. The body weights of mice were measured weekly, and skin alopecia was scored 10 weeks after CD4 + T cell transplantation.
The following score system was used (25) : healthy appearance = 0; skin lesions with alopecia <1 cm 2 in area = 1; skin lesions with alopecia 1-2 cm 2 in area = 2; skin lesions with alopecia >2 cm 2 in area = 3. T cells were sorted by using FACS AriaII (BD Bioscience) (>97% purity). These cells were stimulated with PMA and IM and stained for intracellular cytokines as described here earlier.
Cell isolation
Histology
For hematoxylin and eosin (H&E) staining, liver, lung, and skin tissue samples from mice transplanted with human CD4 + or CD8 + T cells were fixed with 10% buffered formalin and embedded in paraffin. Tissue sections that were 3 lm thick were placed on silane-coated glass slides (Muto Pure Chemicals, Tokyo, Japan) and dewaxed. The slides were stained with hematoxylin (Merck Ltd., Tokyo, Japan) and eosin (Muto Pure Chemicals) solutions. For immunohistochemistry, skin sections were prepared in the same manner as described earlier and were immunostained with anti-human CD4 (Nichirei Bioscience Inc., Tokyo, Japan), anti-mouse Ly-6G (Gr-1) (ReliaTech GmbH, Wolfenb€ uttel, Germany), anti-mouse F4-80 (Bio-Rad AbD Serotec Ltd., Oxford, UK), and anti-mouse CXCL1 and anti-mouse CXCL5 (Bioss antibodies, Woburn, MA) antibodies. Detection and color development including hematoxylin counterstaining were performed using the Bond Polymer Refine
Detection system with a Leica Bond-Max automatic immunostainer (Leica Biosystems, Melbourne, Australia).
Treatment with secukinumab
Secukinumab (trade name, Cosentyx) is an anti-human IL-17A monoclonal antibody produced by Novartis Pharma (Basel, Switzerland) (26) . Four weeks after CD4 + T cell transplantation into NOG mice, 500 lg of secukinumab was intraperitoneally administered every week for 6 weeks, and mice were assessed 10 weeks after transplantation.
Neutrophil depletion
To deplete murine neutrophils, we used a neutrophil-specific Ly6G antibody (clone; 1A8) (BioXcell, West Lebanon, NH) as previously described (27) . After 3 weeks from CD4 + T cell transplantation, 100 lg of Ly6G or rat IgG2b isotype control antibody (BioXcell) was intraperitoneally administered three times a week for 6 weeks ( Figure 8A ). PB and skin samples from all the mice were analyzed at 9 weeks after transplantation.
Statistics
Numerical data are presented as means AE SEM unless otherwise noted. Two-tailed Student's t-tests or two-way analyses of variance were calculated by using Excel (Microsoft, Remond, WA) or Prism 6 (GraphPad, San Diego, CA) software. Pearson's correlation coefficient (r) was calculated using Prism6 (GraphPad). Significant differences are identified as *p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.00005.
Results
Xeno-GVHD symptoms in CD4 + or CD8 + T celltransplanted NOG mice To examine the role of human CD4 + and CD8 + T cells during the onset of xeno-GVHD, we isolated each cell fraction (>97% purity) from PBMCs and transferred them into NOG mice ( Figure 1A ). The weight of CD4 + T celltransplanted mice decreased beginning 6 weeks after transplantation, and approximately 30% of the mice died within 13 weeks. Conversely, more than 90% of CD8 + T cell-transplanted mice survived with no loss in body weight ( Figures 1B and C) .
Next, we investigated the engraftment of human CD4 + or CD8 + T cells in NOG mice. The frequency of human leukocytes in PB gradually increased between 2 and 8 weeks after human CD4 + T cell transplantation. In contrast, leukocyte engraftment was not observed in most CD8 + T cell-transplanted mice ( Figure 2A ). No contamination with other types of human leukocytes was identified in the PB of CD4 + or CD8 + T cell-transplanted mice ( Figure 2B ). Histological analyses revealed severe T cell-transferred NOG mice during this period. *p < 0.05, **p < 0.005, ***p < 0.0005, and ****p < 0.00005. infiltration of lymphocytes into the lung, liver, and skin of CD4 + T cell-transplanted mice but not CD8 + T celltransplanted mice ( Figure 2C ). To examine whether donor human CD4 + T cells recognize murine MHC molecules, we transferred CD4 + T cells into MHC class II-deficient I-Ab knockout (KO) NOG mice. At 6 and 9 weeks after CD4 + T cell transplantation, the engraftment of human cells was significantly decreased in I-Ab KO/ + and I-Ab KO/KO mice compared with conventional NOG mice. Engraftment was completely abrogated in I-Ab KO/ KO mice. These data indicated that human CD4 + T cells recognized the host MHC molecules in NOG mice and proliferated and contributed to xeno-GVHD symptoms, whereas CD8 + T cells did not.
CD4 + T cells support engraftment and expansion of CD8
+ T cells to induce severe GVHD Severe GVHD symptoms and extensive proliferation of CD8 + T cells were observed in our previous xeno-GVHD model in which human PBMCs were transplanted into NOG mice. In contrast, no engraftment of CD8 + T cells and no GVHD symptoms were observed in NOG mice transplanted with human CD8 + T cells alone. Therefore, we hypothesize that CD4 + T cells support engraftment and activation of CD8 + T cells to induce GVHD. To investigate this hypothesis, we transplanted various numbers (2, 0.5, 0.125, or 0 9 10 6 cells) of human CD4 + T cells together with 2 9 10 6 CD8 + T cells into NOG mice. The engraftment of human leukocytes was significantly enhanced when 2 or 0.5 9 10 6 CD4 + T cells were transplanted into the mice ( Figure 3A) . Additionally, the weight of these mice decreased by 20-30% at 8 weeks after transplantation ( Figure 3B ). One mouse transplanted with 2 9 10 6 CD4 + T cells died 5 weeks after transplantation ( Figure 3C ). No GVHD symptoms were observed after cotransplantation of 0.125 9 10 6 or no CD4 + T cells ( Figure 3B ). Engrafted CD8 + T cells were observed in 20-50% of total spleen cells in mice transplanted with 2 or 0.5 9 10 6 CD4 + T cells ( Figure 3D ). These results suggest that human CD4 + T cells support the engraftment and expansion of CD8 + T cells and coordinate the induction of GVHD pathology.
Th1 cytokines such as IFNc and IL-2 stimulate the proliferation and activation of CD8 + T cells. Therefore, we examined whether CD8 + T cells can induce GVHD when transplanted into NOG hIL-2 Tg mice, which produce hIL-2 systemically. The body weight of CD8 + T cell-transplanted NOG hIL-2 Tg mice decreased between 2 and 8 weeks after transplantation ( Figure 4A ). All mice were dead by 8 weeks after transplantation ( Figure 4B ). Most of the engrafted CD45 + cells in the PB were CD8 + T cells, and there were significantly more CD8 + T cells in hIL-2 Tg mice than in non-Tg NOG mice ( Figure 4C ). 
CD62L
À CD45RA + ) cells (28) . Previous studies have demonstrated that the most engrafted human T cells in xeno-GVHD mice differentiated into CM or EM cells (29) . This is most likely because human T cells recognize murine MHC molecules and therefore acquire effector functions similar to allo-GVHD.
In this study, we also examined the phenotype of engrafted human CD8 + T cells in NOG and NOG hIL-2 Tg mice. CM and EM CD8 + T cells increased significantly in hIL-2 Tg mice compared with non-Tg NOG mice during GVHD ( Figures 4D and E) . The majority of CD8 + T cells in non-Tg NOG mice exhibited TDEM phenotypes, indicating that they were senescent or exhausted T cells with limited response to T cell receptor stimulation (30) . These results suggest that human IL-2 plays a crucial role in the development of CM or EM CD8 + T cells, resulting in severe GVHD pathology.
Pathogenic IL-17/IFNc-producing cells induced severe cutaneous GVHD in CD4 + T cell-transplanted NOG mice Transplantation of human CD4 + T cells into NOG mice resulted in characteristic alopecia or skin inflammation. CD4 + T cell-transplanted mice exhibited progressive hair loss ( Figure 5A ), which is a known pathology of human allo-GVHD (31). Alopecia was even more severe when NOG mice were transplanted with CD4 + T cells compared with that observed with CD8 + T cells alone ( Figure 5B ).
To investigate the characteristics of skin-homing CD4 + T cells, we isolated lymphocytes from the skin and examined the expression of skin-resident T cell markers, such as CCR4 and CLA. CCR4 is a Th17-related chemokine receptor that binds to chemokines CCL17 and CCL22, which are produced by the skin and has been proposed as a critical mediator of skin-specific T cell homing in mice and humans (32, 33) . After isolation of human T cells from skin and spleen of CD4 + T cell-transplanted NOG mice, cell number was counted ( Figure 5C ). The frequency of CD4 + T cells that expressed both CLA and CCR4 was higher in the skin of CD4 + T cell-transplanted NOG mice than in the spleen or human PBMC ( Figure 5D ). 
CD4
+ T cells ( Figure 5E ).
We also assessed the frequency of IL-17-and/or IFNc-producing cells in the skin-homing human CD4 + T cells of transplanted mice. We found that 10% of CD4 + T cells expressed IL-17 and IFNc in the skin, which was higher (Figures 5F and G) . These data suggest that CD4 + T cells that produce IL-17 and IFNc induce skin inflammation and severe alopecia during GVHD.
Suppression of human IL-17 ameliorates cutaneous xeno-GVHD
To investigate whether inhibition of human IL-17 prevents skin inflammation, we administered an anti-human IL-17 antibody (secukinumab) weekly into the peritoneal of CD4 + T cell-transplanted NOG mice ( Figure 6A ). Severe alopecia was almost completely inhibited by secukinumab treatment (Figures 6B and C) . A decrease in body weight was slightly ameliorated in the secukinumab-treated group than in the saline-treated group, but the difference was not significant ( Figure 6D ). Furthermore, H&E staining of the skin revealed reduced epidermal hyperplasia and leukocyte infiltration into the tissues of secukinumab-treated mice ( Figure 6E ). Infiltration of human CD4 + T cells into the skin was not suppressed ( Figure 6F ). In addition, the frequency of IFNc + IL-17 + cells was not altered by secukinumab treatment in the CD4 + T cell population ( Figure 6G ).
To identify IL-17-responding inflammatory cells other than human CD4 + T cells, we performed immunohistochemistry to detect murine innate immune cells such as macrophages and neutrophils. Skin-infiltrated neutrophils were significantly reduced by secukinumab treatment (Figures 7A and B) . However, accumulation of macrophages in the skin was not affected by secukinumab treatment ( Figure 7A ). Further, we investigated the expression of murine neutrophil-mobilizing chemokines, CXCL1 and CXCL5, in the skin of CD4 + T cell-transferred mice with or without secukinumab treatment. The number of each chemokine-producing cell type was substantially decreased in the skin of secukinumab-treated mice ( Figure 7C ). These results indicate that human IL-17 produced by pathogenic Th17 cells induced severe alopecia, epidermis hyperplasia, and murine neutrophil infiltration during CD4 + T cell-mediated xeno-GVHD. Suppression of an alopecia symptom by murine neutrophil depletion Finally, to investigate the role of neutrophils in the alopecia, we attempted to deplete murine neutrophils by using a Ly6G antibody, which can specifically remove neutrophils in vivo (27) . A complete lack of neutrophils was observed in PB of Ly6G antibody-treated mice but not of isotype control antibody-treated mice ( Figure 8B ). At 6 and 9 weeks after transplantation, the onset of alopecia in the skin was more suppressed by Ly6G antibody treatment than by isotype control treatment ( Figures 8C and D) . In histology, murine neutrophils markedly decreased but still slightly remained in the skin of Ly6G-treated mice ( Figure 8E ). Then, the alopecia score was strongly correlated with the number of skin-infiltrated neutrophils in control or Ly6G antibody-treated mice, suggesting the involvement of murine neutrophils in alopecia during CD4 + T cell-induced cutaneous GVHD ( Figure 8F ).
Discussion
In this study, we analyzed the functional roles of human CD4 + or CD8 + T cells in xeno-GVHD byy using NOG mice. We revealed that CD4 + and CD8 + T cells contribute differently to the pathogenesis of GVHD.
Although purified CD8
+ T cells did not engraft in conventional NOG mice, these were shown to highly engraft and induce severe symptoms of GVHD when transferred into NOG hIL-2 Tg mice or into NOG mice together with at least 0.5 9 10 6 CD4 + T cells. This demonstrated that CD4 + T cells supported engraftment and expansion of CD8 + T cells through the IL-2 signaling pathway to induce GVHD. Zhang et al reported that CD8
+ memory T cells were highly differentiated from CD8 + na€ ıve T cells during allo-GVHD and acquired the ability to rapidly proliferate and expand in response to host dendritic cells in the presence of IL-2, IL-7, and IL-15 (34) . On the other hand, isolated memory T cells do not induce GVHD in both mouse and human studies (35, 36) . This result has described that antigen-experienced T cells have reduced reactivity to other antigens. Consistent with the evidence, we showed that the majority of engrafted human + T cells acquired effector functions and differentiated into EM T cells to induce severe symptoms of GVHD in the presence of human IL-2.
Next, we investigated the pathogenesis of skin inflammation induced by CD4 + T cells. We previously developed a xeno-GVHD model by transplanting human PBMCs into NOG mice. These mice expressed severe symptoms, including rapid weight loss and high mortality caused by organ dysfunctions mediated by CD4 + and CD8 + T cells (20) . In NOG mice with transplanted CD4 + T cells, GVHD symptoms were considerably reduced compared with the PBMC-transplanted model. For example, all PBMC-transplanted NOG mice died within 1.5 months after transplantation, whereas most CD4 + T cell-transplanted NOG mice survived >3 months, although nearly equal numbers of cells were transplanted. PBMC-transplanted NOG mice did not have significant skin inflammation. However, CD4
+ T cells accumulated in the skin of NOG mice with transplanted CD4 + T cells. This suggests that the transplantation of CD4 + T cells alone was not sufficient to induce lethal GVHD, but these cells may acquire organ-tropism for migration to the skin. Interestingly, a large number of CLA + CCR4 + cells were observed in the skin but not the spleen of CD4 + T cell-transplanted NOG mice. Several studies have reported that most of CLA + skin-homing T cells express CCR4 on their surface, and the CCL17 ligand is predominantly produced from cutaneous venules to attract CD4 + T cells to the skin (37) (38) (39) (40) (41) . Thus, we speculate that human CCR4 + T cells are recruited to the skin using murine CCL17 secreted from cutaneous venules in our CD4 + T cell-transplanted mice because CCR4 may react with CCL17 across species (42) . This could explain the exacerbated skin inflammation we observed in these mice.
A transfer experiment of purified CD4 + T cells into NSG, NSG I-Ab KO, or NSG HLA-DR4 Tg mice was also reported previously. (21) . Similar to our findings, NSG IAb KO mice showed lower engraftment ratio of human T cells than NSG mice did when purified CD4 + T cells were transferred. Further, they also described that weight and hair loss were observed in those CD4 + T cell-transferred conventional NSG mice. This study provides encouraging evidence that the symptoms of CD4-mediated GVHD are reproducible, albeit by using different donor PBMCs. In contrast to our results, lethal GVHD symptoms were observed in which 50% of CD4 + T cell-transferred mice died around 6 weeks after transplantation, even in conventional NSG mice. The different symptoms from our result can be explained by different conditions of the mice for CD4 transplantation-because those mice were irradiated with 2 Gy before transplantation for induction of xeno GVHD, this can induce the lethal symptoms. Raising severity of xeno-GVHD symptoms in irradiated NOG mice has been reported in our previous study (20) .
In murine allo-GVHD models, Th17 cells contribute to the pathogenesis of skin inflammation (5, 43, 44) . Carlson et al transplanted in vitro differentiated Th17 cells into the allorecipient and observed skin inflammation that was markedly reduced by neutralization of IL-17 (43) . Nishimori et al also demonstrated that pathogenic murine Th17 cells that produced IFNc and IL-17 were generated during allo-GVHD and contributed to the onset of GVHD (5). We first reported accumulation of pathogenic human Th17 cells in the skin that caused cutaneous GVHD including leukocyte inflammation and severe alopecia. Strikingly, these symptoms were suppressed by secukinumab treatment, which neutralizes IL-17 (26) . We concluded that IL-17 triggers cutaneous GVHD, even in humans.
We also demonstrated that murine neutrophils infiltrated the skin of our CD4 + T cell-mediated cutaneous GVHD model, and this was suppressed by secukinumab treatment. During IL-17-induced pulmonary inflammation, neutrophil-mobilizing chemokines such as CXCL1, CXCL2, and CXCL5 were significantly upregulated in lung tissues and induced neutrophilia (45, 46) . Further, IL-17 stimulation promotes neutrophil-mobilizing chemokine production from epidermal keratinocytes and diffuses hyperplasia with aberrant proliferation of keratinocytes in patients with psoriasis (47) . These mechanisms may explain the findings of our study, since the production of neutrophil-mobilizing chemokines CXCL1 and CXCL5 was suppressed by IL-17 inhibition. We propose that human IL-17 binds to murine IL-17 receptors expressed on murine keratinocytes, and they produce neutrophil-mobilizing chemokines that recruit neutrophils. We further attempted to elucidate the role of murine neutrophils in the alopecia symptoms by neutrophil depletion. Interestingly, the skin symptom was suppressed by administration of Ly6G antibody than by control antibody. Although the smaller number of neutrophils has been remained even in Ly6G antibody treatment, a good correlation was observed between the neutrophil number and alopecia symptom. This evidence may help to understand the mechanisms of the contribution of neutrophils in Th17-mediated skininflammatory diseases, such as atopic dermatitis, psoriasis, and cutaneous GVHD; however, further analyses on the role of monocyte/macrophages in skin inflammation are required to fully elucidate the involved mechanisms.
In conclusion, we have developed two novel humanized mouse models: (a) an IL-2-induced xeno-GVHD model mediated by human CD8 + T cells and (b) a human CD4 + T cell-mediated cutaneous GVHD model. In the latter model, cutaneous symptoms were induced by IL-17 produced from pathogenic human Th17 cells, and these were suppressed by secukinumab treatment. These models will likely be useful in the analysis of cellular and molecular mechanisms underlying human GVHD and for the preclinical development of novel therapeutic drugs.
